On the Horizon 

We are constantly developing new and innovative algorithms and user experiences to empower doctors and patients. Together, Progenics and EXINI are reimagining the combination of diagnostics, treatments and information systems in cancer care to support the patient from referral to disease management and remission.


PSMA-AI CAD is the first software being developed by EXINI tailored to Progenics’ imaging agent pipeline. PSMA-targeted imaging agents attach to a protein called PSMA which is overexpressed on the surface of prostate cancer cells. The agents are labeled with a radioactive molecule and are thus detectable by imaging. Central to PSMA-AI CAD is the automatic and quantitative computation of assessments used to detect and stage localized and advanced prostate cancer1. The technology is based on deep learning and convolutional neural networks that determine a detailed anatomical context from a CT image. This information is combined with functional information from the corresponding PSMA image to extract the most relevant information for estimating cancer prevalence and growth.
  1. K.Sjöstrand, A.Anand, J.Richter, K.Johnsson, K.Gjertsson, L.Edenbrandt, V.Wong: Automated Detection and Quantification of Prostatic PSMA Uptake in SPECT/CT using a Deep Learning Algorithm for Segmentation of Pelvic Anatomy. SNMMI 2018.